PharmaJet Inc. has partnered with Immuno Cure to develop a needle-free HIV therapeutic DNA vaccine. The agreement, signed on June 16, 2025, during the BIO International Convention in Boston, will utilize PharmaJet’s Tropis system in a human clinical trial for their ICVAX vaccine.
This collaboration follows the success of an earlier Phase 1 trial of ICVAX, which demonstrated safety and promising effectiveness. Immuno Cure aims to use the Tropis system to enhance vaccine performance and patient experience by leveraging intradermal delivery, which can activate the body’s immune response more effectively than traditional intramuscular methods.
Dr. Xia Jin, CEO of Immuno Cure, expressed excitement about the partnership, stating, “At Immuno Cure, our mission is to advance transformative therapies for infectious diseases and cancer. We are excited to partner with PharmaJet and leverage their Tropis Needle-free Injection System on our HIV therapeutic DNA vaccine program.”
Golden-based PharmaJet’s technology has already been used in more than 12 million injections and is recognized for its safety and effectiveness in generating immune responses.